Industrial Policy & Trade Monitor· 2663 actions· ✨ 89 recent

The Decreto para la Autorización Inmediata de Inversiones, published in Mexico's Diario Oficial de la Federación on 4 May 2026, creates a streamlined investment-authorization mechanism under President Sheinbaum's Plan México strategy. The decree establishes an Investment Committee — composed of the Secretariats of Economía, Hacienda, SEMARNAT, SCT, Energía, and Bienestar — mandated to issue authorization certificates within 30 business days for qualifying projects, replacing the historic 6–18-month multi-agency backlog. Eligibility covers three tiers: projects in designated Polos de Desarrollo Económico para el Bienestar (Welfare Development Poles), investments of MXN 2 billion (≈USD 100M) or more, and projects in strategic sectors (semiconductors, EV batteries, critical minerals, automotive supply chain, medical devices, biotech, aerospace). This is the procedural- acceleration arm of Plan México, structurally distinct from the January 2025 Plan México tax-incentive decree (the fiscal arm), and operationalises the February 2026 Plan México expansion announced by Sheinbaum.

On 26 April 2026, the UAE Cabinet, chaired by Vice President and Prime Minister Sheikh Mohammed bin Rashid Al Maktoum, approved a four-part industrial-resilience package: (i) a National Industrial Resilience Fund with AED 1 billion (~USD 272m) capital managed by Emirates Development Bank over five years covering food industries, manufacturing, primary metals, mechanical/electrical/chemical industries, pharmaceuticals and medical supplies, advanced technology, and construction — designed to localise over 5,000 critical products and link confirmed procurement demand with targeted financing for local manufacturers; (ii) structural overhaul of the National In-Country Value (ICV) Programme, transitioning it from incentive-based to MANDATORY across federal entities and companies in which the government holds 25% or more; (iii) a National Product Retail Presence Policy strengthening visibility of UAE-manufactured goods in retail and digital channels (Phase 1: bottled water, dairy, eggs, poultry, bread, flour, vegetable oils, seasonal vegetables); and (iv) a National Industrial Data Committee chaired by Hasan Jassim Al Nowais (Undersecretary, MoIAT), with AI-driven forecasting and risk management integrated into industrial-resilience monitoring.

DGFT Notification No. 12/2026-27 (Gazette S.O. 2222(E)), issued 17 April 2026 under sections 3 and 5 of the Foreign Trade (Development and Regulation) Act 1992 and the Foreign Trade Policy 2023, reclassifies high-grade Baryte (Natural Barium Sulphate, ITC(HS) 2511 10 00) Grade A (specific gravity ≥4.2, code 25111010) and Grade B (specific gravity 4.10–4.20, code 25111020) from "Free" to "Restricted" export status, requiring DGFT prior authorisation for all exports in lumps, powder, or other forms. Grade CDW (specific gravity <4.0, code 25111090) remains freely exportable. India produces approximately 80% of global baryte output and the restriction is aimed at ensuring adequate domestic availability for oil-and-gas drilling fluids, radiation shielding, and high-density industrial applications.

Brazil's Foreign Trade Chamber Executive Committee (GECEX/CAMEX) adopted Resolução GECEX nº 855 on 13 February 2026, imposing a five-year definitive antidumping duty on hypodermic needles (agulhas hipodérmicas) originating from China, classified under NCM tariff code 9018.32.19 (other tubular metal needles). The duty is collected as a specific tariff fixed in US dollars per thousand units, with rates ranging from USD 0.23 to USD 25.57/thousand units depending on the Chinese producer/exporter. The measure was published in the Diário Oficial da União (DOU Edição 32) on 18 February 2026, enters into force from publication, and marks the first medical-device trade-remedy action on the IPTM register. Scope exclusions cover insulin needles, biopsy needles, animal insemination needles, anesthesia needles, bulk non-sterile needles, and non-hypodermic needles.

On 9 February 2026 USTR Ambassador Jamieson Greer and Bangladesh Adviser Sheikh Bashir Uddin signed the Agreement on Reciprocal Trade (ART) between the United States and Bangladesh in Washington DC — USTR's first ART signing in South Asia, preceding the US-India interim-trade-framework finalisation by three days. The deal locks the US reciprocal tariff on Bangladesh-originating goods at 19% (down from 35% under the April 2025 IEEPA regime) and establishes a zero-percent mechanism for products on the Annex III aligned- partner list (EO 14346, 5 September 2025). Bangladesh commits to significant preferential market access for US industrial and agricultural goods — including chemicals, machinery, motor vehicles, medical devices, ICT equipment, energy products, soy, dairy, beef, poultry, tree nuts, and fruit — and to eliminating specified non- tariff barriers including acceptance of US Federal motor-vehicle safety and emissions standards, FDA certificates, and prior marketing authorisations for medical devices and pharmaceuticals.

The Beijing Economic-Technological Development Zone (BDA / Yizhuang) Management Committee issued "Several Measures on Accelerating Brain-Computer Interface Technology and Industry Innovation Development" (Jingjiguanfa [2026] No. 2), announced 2026-02-04 and effective 2026-02-06 through 2028-12-31. The package comprises 15 initiatives across three pillars — technology/product development, innovation platform construction, and industrial ecosystem building — aimed at moving the BCI sector from research toward clinical translation and commercialization, positioning Yizhuang as a leading domestic and internationally recognized BCI technology and industry hub. It applies to entities legally operating in Yizhuang New City engaged in BCI R&D, product manufacturing, or platform services. No specific monetary figures are disclosed in the published policy interpretation.

On 26 January 2026 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2026〕2号, "Several Measures of Beijing Dongcheng District on Promoting High-Quality Development of the Pharmaceutical and Health Industry," effective 25 February 2026. The 14-article package spans seven chapters covering traditional-Chinese-medicine industry development, product-innovation value realisation, digital medical services, innovative-medicine support, and talent services, with cash grants of up to RMB 20 million per project and up to RMB 10 million per year for a single market entity in the medical-device segment. A draft version was open for public comment from 18 December 2025 to 17 January 2026 before formal issuance.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 20 million preferred-equity stake in Omniscient Neurotechnology, a Sydney-founded clinical connectomics company, announced 16 January 2026. The investment forms part of Omniscient's broader Series D raise (reported at up to AUD 36 million / USD 27.2 million) alongside Australian venture fund OIF Ventures, and is earmarked to commercialise Omniscient's Quicktome AI brain-mapping platform globally and expand its data-science team. NRFC frames the deal as building sovereign AI/medical-technology capability and creating over 40 new skilled jobs in Australia.

Brazil's Câmara de Comércio Exterior (Gecex) approved Resolução nº 844, de 30 de dezembro de 2025, amending Annexes IV and V of the base tariff-nomenclature resolution (Gecex nº 272/2021) to modify import tariff-rate quotas (TRQs) and duties on 15 products, effective 1 January 2026. The resolution establishes new duty-free (0%) TRQs for 11 product categories — including nutritional supplements (30 metric tons/year), animal-feed additives, contact lenses (a combined 40.375 million units/year across two NCM headings), electrical cable connectors, and glass ampoules — while removing existing duty-free quota treatment for four products (a thermal-control polyethylene film, a rubber sanitary/contraceptive item under NCM 4014.10.00, an anhydrous sodium-compound chemical under NCM 2836.20.10, and one further excluded product), whose duty reverts from 0% to the standard Mercosur Common External Tariff (TEC) rate. The measure is a routine periodic tariff-schedule maintenance action rather than a trade-remedy or policy-driven restriction.

China's State Council Tariff Commission published its annual "2026 Tariff Adjustment Plan" (税委会公告2025年第11号) on 29 December 2025, effective 1 January 2026. The plan sets provisional import tariff rates below MFN levels on 935 products, while cancelling provisional rates on certain other products (reverting them to standard MFN rates). It adds new national tariff subheadings for intelligent bionic robots, bio-aviation kerosene, forest-grown ginseng, and other items, bringing the total tariff schedule to 8,972 lines. The government frames the provisional-rate cuts — covering key components and advanced materials such as CNC hydraulic air cushions for stamping presses, recycled "black powder" (黑粉) lithium-ion battery feedstock, artificial blood vessels and infectious-disease diagnostic kits — as support for "high-level sci-tech self-reliance" and modernisation of the industrial system. China also continues zero-tariff treatment on 100% of tariff lines for the 43 least-developed countries with diplomatic relations with China, and continues Asia-Pacific Trade Agreement preferential rates for Bangladesh, Laos, Cambodia and Myanmar.

On 25 December 2025 Shanghai's Huangpu District Science and Technology Commission and Investment Promotion Office jointly issued Huangkeweigui [2025] No. 3, "Several Measures of Huangpu District on Promoting Brain-Computer Interface Innovation and Transformation Services (Trial)" (informally the "BCI Service 10 Provisions"), effective 24 January 2026 and valid through 31 December 2027. The measures subsidize BCI core- technology R&D and district co-funding of national/municipal projects (up to CNY 2m, 1:1 district match), shared innovation-platform construction (up to 30% of investment, capped CNY 2m), registered medical-device commercialisation (up to 40% of R&D cost, capped CNY 5m/ year per entity), application-demonstration scenarios (up to 30% of investment, capped CNY 2m), enterprise-growth and unicorn/gazelle recognition rewards (CNY 20k-100k), industrial-park operator support (up to CNY 2m/year), equity-financing support (up to 10% of R&D cost, capped CNY 2m, for firms with ≥CNY 20m in equity funding), and international BCI conference/event sponsorship (up to 30%, capped CNY 500k).

On 9 December 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) issued the December 2025 batch expansion of its Mandatory List — a binding instrument requiring government entities, state-owned enterprises, and sub-contractors to source listed products exclusively from Saudi domestic manufacturers meeting the LCGPA-defined local-content threshold. The December 2025 expansion brings the list to approximately 1,444 national products across 16 sectors, effective 1 March 2026, with LCGPA targeting a total of approximately 2,000 products by end-2026. The Mandatory List operationalises the demand-side layer of Saudi Arabia's Vision 2030 / National Industrial Strategy (NIS) industrial-policy stack, directly restricting foreign-supplier access to Saudi annual government-procurement budgets estimated at SAR 500 billion+ across central government, Aramco, PIF-portfolio entities, Ma'aden, SEC, STC, Saudi Post, and Saudi Railway.

Brazil's Câmara de Comércio Exterior (Gecex) approved Resolução nº 821, de 1º de dezembro de 2025, amending Annex V (Letec — List of Exceptions to the Common External Tariff) and Annex X (List of Temporary Exceptions for Automotive Products under ACE 14) of the base tariff-nomenclature Resolução Gecex nº 272/2021. The resolution took effect on the date of its publication in the Diário Oficial da União. Global Trade Alert tracks the measure as four discrete tariff-line interventions bundled under one state act: (1) an import-tariff increase on butyl and sodium-polyacrylate chemical inputs, effective 5 December 2025; (2) a reduction of the import tariff to zero for a pharmaceutical product under NCM 3004.90.79, effective 5 December 2025; (3) a new import tariff-rate quota for a chemical/pigment product under NCM heading 3306.11, effective 5 December 2025; and (4) an import-tariff increase on 16 medical-device products under NCM 9018.90.99, effective 2 December 2025. Two of the four sub-measures are duty increases (harmful to importers) and two are duty reductions/new liberalising quotas — consistent with Gecex's routine periodic tariff-schedule maintenance cycle rather than a targeted trade-remedy or industrial-policy action.

On 24 November 2025, six Beijing municipal departments — the Bureau of Economy and Information Technology, Development and Reform Commission, Science and Technology Commission, Health Commission, Drug Administration and Medical Insurance Bureau — jointly issued Notice 京经信发〔2025〕50号 ("Several Measures to Promote High-Quality Development of the Beijing Medical Device Industry"), effective immediately through 31 December 2028. The 15-measure package subsidises the full medical-device value chain: early-stage innovation (up to RMB 1m per project), product approval/launch (up to RMB 2m per product, RMB 10m annual enterprise cap), industrial-park and public-service infrastructure construction (up to 50% of investment, capped at RMB 50m), supply-chain-resilience R&D for critical components/materials (up to 30% of investment, capped at RMB 30m), AI-diagnostic-model development (up to RMB 30m), smart-factory digitalisation (up to 30% of investment, capped at RMB 30m per project), and international regulatory approval/market entry (up to RMB 1m per product, RMB 3m annual cap; up to RMB 10m for introducing overseas products to China).

On 5 February 2026, USTR Ambassador Jamieson Greer and Argentine Foreign Minister Pablo Quirno signed in Washington the United States-Argentina Agreement on Reciprocal Trade and Investment (ARTI), formalising the framework jointly announced on 13 November 2025. The agreement is the first standalone bilateral trade-and-investment instrument concluded by the second Trump administration and the first FTA-style agreement signed under the post-IEEPA reciprocal-tariff architecture (Executive Order 14257, "Liberation Day"). On the US side, the ARTI sets out three tariff schedules: (i) Schedule 2A suspends additional reciprocal tariffs under EO 14257 for specified Argentine-origin goods (covering "unavailable natural resources" and non-patented pharmaceutical inputs); (ii) Schedule 2B grants a zero additional reciprocal tariff for designated Argentine agricultural products under EO 14360; and (iii) caps additional ad-valorem duties on other goods at 10% above MFN rates, inclusive of IEEPA reciprocal tariffs. On the Argentine side, illustrative tariff-rate quotas include duty-free access for 80,000 MT of US beef in calendar year 2026, 1,000 MT for cheese, 870 MT for almonds, 40 MT in-shell + 40 MT shelled for pistachios, 80,000 litres for wine (<2 L bottles), and preferential treatment for 10,000 motor vehicles meeting defined technical parameters. Argentina additionally commits to broader preferential market access on medicines, chemicals, machinery, information-technology products, medical devices, and a wide range of agricultural goods, alongside IP-enforcement upgrades (counterfeit/pirated-goods enforcement, patentability criteria, patent-backlog reduction, geographical indications) and investment-facilitation commitments that align Argentina's regime with US-preferred standards on regulatory cooperation, labour and environment.

Japan's Ministry of Economy, Trade and Industry amended the Export Trade Control Order (輸出貿易管理令) to add four technology categories to the prior-notification-of-transfer list under the Technology Management Scheme through Public-Private Dialogue (TMS-PPD): quantum-dot materials, TADF (thermally-activated delayed fluorescence) emissive materials, phase-difference film, and flexible endoscopes. Announced 11 November 2025, promulgated 19 November 2025, and effective 19 January 2026. This is the first list-control update produced by the TMS-PPD mechanism, which was established in December 2024 as an annual METI–industry review process for adding emerging-technology items to prior-notification controls outside the slower Wassenaar Arrangement / FEFTA catch-all channels.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 54 million (~USD 35 million) equity stake in Synchron, a Melbourne-founded (now US-headquartered) brain-computer interface company, announced 7 November 2025. The investment forms part of Synchron's broader ~AUD 305-308 million (~USD 200 million) Series D raise alongside investors including Qatar Investment Authority, In-Q-Tel and Double Point Ventures, and is earmarked to fund final clinical trials and US FDA regulatory approval of Synchron's Stentrode device — a minimally-invasive BCI implanted via blood vessel without open brain surgery. NRFC frames the deal as commercialising Australian-origin technology and building sovereign medical-device manufacturing and clinical-trial capability.

On 28 October 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) signed five localization and knowledge-transfer agreements on the sidelines of the Global Health Exhibition 2025, covering domestic manufacture and technology transfer for the biologic drugs etanercept and adalimumab (both used to treat chronic inflammatory / autoimmune conditions) and for orthopedic trauma implants. The adalimumab agreement was signed separately with Boston Oncology Arabia and Tabuk Pharmaceuticals. Boston Oncology's own disclosure of its adalimumab/ etanercept agreement (announced 4 November 2025) put the combined economic impact at over SAR 1.2 billion in cumulative GDP contribution and approximately 500 direct jobs, with production sited at its Sudair Industrial City facility (USFDA/EMA/SFDA-standard). Global Trade Alert's tracking of the same state act records seven counterparties in total (Boston Oncology, Tabuk Pharmaceuticals, Rameem Medical, Bio Vision, Sudair Pharma, Almana Company, and an additional pharma manufacturer), consistent with LCGPA's practice of bundling several related product-localization signings into one event.

The European Investment Bank (EIB) signed a EUR 400 million loan agreement with Fresenius on 8 September 2025 in Bad Homburg, Germany, to finance research, development and innovation activities and capacity expansion for Fresenius Kabi's manufacturing of biosimilars, generic drugs, infusion therapies, clinical nutrition products, and associated medical devices across EU member states. The financing is explicitly framed by both parties as strengthening the resilience of European pharmaceutical production and security of supply for EU healthcare systems.

The Hainan Provincial People's Government General Office issued "Several Policy Measures of Hainan Province for Further Supporting High-Quality Development of the Biopharmaceutical Industry" (Qiong Fu Ban [2025] No. 38) on 2025-08-14, effective 2025-09-13 for a three-year term. The package disburses provincial subsidies across the full biopharma value chain — R&D-stage grants, national centralized-procurement awards, international-certification bonuses, platform-investment reimbursement, and traditional-Chinese-medicine insurance-listing awards — leveraging Hainan Free Trade Port status to build a regional biomedical industry cluster.

Brazil's Inter-Ministerial Commission for Novo PAC Innovations and Acquisitions (CIIA-PAC/CC), under the Casa Civil, published Resolução CIIA-PAC/CC nº 3, de 28 de julho de 2025 in the Diário Oficial da União on 2025-07-31. The resolution designates a list of manufactured healthcare equipment (primary and specialised care items, e.g. vaccine cold-storage units, digital retinographs, electrocautery devices, defibrillators, surgical tables, anesthesia machines, rigid videoendoscopy systems) that qualifies for a public -procurement preference margin under Decreto nº 11,889/2024 and Art. 26 of Lei nº 14,133/2021. Qualifying domestically manufactured products can win public tenders even when priced 10-20% above imported equivalents, provided the manufacturer holds BNDES Finame accreditation and meets national-technology (TECNAC) content criteria. The measure accompanies an announced BRL 2.4 billion government purchase of over 10,000 healthcare equipment units for Brazil's public health system (SUS).

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, committed AUD 150 million to Brandon Capital's Brandon BioCatalyst 6 (BB6) fund, announced 24 July 2025. Brandon Capital — Australasia's largest life-sciences venture capital manager, with over AUD 1 billion under management — closed BB6 at AUD 439 million total, with the NRFC contribution the largest single commitment. The fund backs early- and late-stage Australian medical-science companies developing therapeutics, medical devices and vaccines, with roughly one-third earmarked for early-stage ventures and the remainder for late-stage clinical development and commercialisation. NRFC frames the deal as building sovereign medical-manufacturing and R&D capability and keeping Australian biotech IP and jobs onshore rather than migrating offshore for follow-on capital.

The European Commission approved up to EUR 403 million in State aid from France, Hungary, Italy, Slovakia and Slovenia to fund Tech4Cure, the second health-related Important Project of Common European Interest (IPCEI). The scheme backs ten companies (including six SMEs) on R&D and first industrial deployment of medical devices integrating digital and AI technologies across cardiovascular disease, paediatrics, oncology, neonatal care and ophthalmology, targeting "3P" (predictive, preventive, personalised) medicine. The Commission expects the public funding to leverage an additional EUR 826 million in private investment.

Brazil's Câmara de Comércio Exterior (Gecex) approved Resolução nº 756, de 7 de julho de 2025, amending Annexes V, VI and X of the base tariff-nomenclature resolution (Gecex nº 272/2021, the instrument that adapted Brazil's Common Mercosur Nomenclature/Common External Tariff schedule to the 2022 Harmonized System revision). The amendment changes import tariffs and tariff-rate quotas for a narrow set of product lines including airport fire-fighting vehicles (NCM 8705.30.00), sterile saline flush and elevator guide rails, with a companion Portaria Secex nº 410/2025 setting the quota-allocation criteria. Global Trade Alert flags China, Germany and Italy as the principal affected trading partners.

China's Ministry of Finance issued Caiku [2025] No. 19 on 3 July 2025, effective 6 July 2025, restricting EU-origin medical devices in Chinese government procurement. For procurement projects with budgets of CNY 45 million (~USD 6.3 million) or more, purchasers must exclude EU enterprises (excluding EU-invested enterprises operating in China) from participation where imported products are genuinely required; non-EU bidders that do participate may not source more than 50% of the contract value from EU-imported medical devices. Contracts already awarded before the effective date are grandfathered. The notice is explicitly framed as a reciprocal response to the European Commission's 20 June 2025 measure restricting Chinese medical-device firms and products from EU public procurement under the EU's International Procurement Instrument (IPI).

The European Commission adopted Commission Implementing Regulation (EU) 2025/1197 on 19 June 2025, published in the Official Journal on 20 June 2025 and applicable from 30 June 2025. It imposes the EU's first-ever International Procurement Instrument (IPI) measure, excluding tenders submitted by economic operators originating in China from EU public procurement contracts for medical devices (CPV codes 33100000-1 to 33199000-1) valued at EUR 5,000,000 or more net of VAT. Even where a non-Chinese bidder wins, no more than 50% of the contract's value may be sourced from China-origin medical devices (IPI Article 8(1)). Contracting authorities may waive the measure only where solely Chinese bidders meet requirements or for overriding public-interest reasons (IPI Article 9(1)).

On 2025-06-02 Mexico published a presidential decree ("DECRETO por el que se fomenta la inversión en territorio nacional, para fortalecer el desarrollo de la industria farmacéutica y la producción de insumos para la salud; así como el desarrollo de investigación científica nacional") in the Diario Oficial de la Federación, effective 2025-06-03. Starting with fiscal-year 2026 consolidated federal purchases of medicines, health inputs and medical devices (for 2027 delivery), the Secretaría de Salud will apply a points-and-percentage evaluation scheme that favors bidders holding productive investment or infrastructure (plants, laboratories, warehouses) in Mexico, or that conduct scientific research domestically. A tri-ministry Promotion Committee (Health, Economy, and the Anticorruption/Public Function ministry) will vet investment commitments, and the decree directs the Secretaría de Salud to issue implementing guidelines within 90 calendar days of publication.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 27 million equity stake in PolyActiva, a Melbourne biotech developing a biodegradable ocular implant (Prezia/PA5108) that delivers glaucoma medication over 6-12 months as an alternative to daily eye drops. The investment, announced 30 May 2025, forms the majority of PolyActiva's AUD 40 million Series C round, with the remaining AUD 13 million from existing investor Brandon Capital. Funds will consolidate the company's R&D, analytics and manufacturing into a single Melbourne facility, grow its ~25-person workforce, and fund completion of a Phase 2b clinical trial, with commercialisation targeted for 2029.

Japan's National Diet passed a partial amendment to the Pharmaceutical and Medical Device Act (PMD Act / 薬機法) on May 14, 2025, promulgated as Law No. 37 of 2025 on May 21. The amendment requires every Marketing Authorization Holder (MAH) to designate a Supply System Manager responsible for reporting supply disruptions to MHLW, and grants MHLW authority to order replacement of key quality personnel when systemic deficiencies are found. It also reforms GMP oversight to a risk-based inspection model and expands the conditional-approval pathway for rare disease and paediatric drugs. Enforcement is staggered across three tranches: November 2025, May 2026, and final full implementation by May 2027.

The Government of Karnataka, Department of Industries and Commerce, notified the Karnataka Industrial Policy 2025-30 in the Karnataka Gazette on 11 February 2025, with the policy taking legal effect from 8 February 2025 and valid for five years (or until superseded). It supersedes the prior Karnataka Industrial Policy 2020-25. The umbrella state-level framework targets ₹7.5 lakh crore (~USD 90 bn) in fresh investment and 20 lakh (2 million) new jobs by 2030, positioning Karnataka as a top-Asia destination for high-technology manufacturing — semiconductors, EVs, aerospace, defence, biotech, medical devices, textiles and renewable energy. It introduces zone-based incentive categorisation (Zone 1/2/3 district classification), capital subsidies, stamp-duty exemption, electricity-tax exemption, interest subsidy, ESDM-specific top-up incentives that layer onto central PLI/ECMS/Semicon Mission schemes, and a Cabinet Sub-Committee under the Chief Minister to sanction bespoke "Anchor Investor" and "Mega/Ultra-Mega" customised incentive packages.

The U.S. Department of the Treasury's Office of Foreign Assets Control (OFAC) issued a final rule amending three sanctions programs. The rule adds a new general license at 31 CFR § 525.512 to the Burma Sanctions Regulations authorizing the provision of agricultural commodities, medicine, medical devices, replacement parts and components for medical devices, and software updates for medical devices to individuals whose property and interests in property are blocked. It also updates the authorities section of the Burma Sanctions Regulations to reflect recent legislation, replaces "the Office of Foreign Assets Control" / "the Director of the Office of Foreign Assets Control" with the acronym "OFAC" in three sections of the Sudan Stabilization Sanctions Regulations, and corrects a cross-reference in the Ukraine-/Russia- Related Sanctions Regulations. The rule is effective on publication.

The Bureau of Industry and Security (BIS) issued a final rule amending the Russia and Belarus sanctions under the Export Administration Regulations (EAR) to add License Exception Medical Devices (MED) at 15 CFR 740.23. The new exception authorises, without an individual licence, exports, reexports, and in-country transfers of EAR99 medical devices and EAR99 parts/components/accessories for exclusive use with such devices to Russia, Belarus, the temporarily occupied Crimea region of Ukraine, and the other covered regions of Ukraine. The exception carries verification conditions and excludes Entity List / military end-user recipients, "production" facilities, and any case where the exporter has knowledge the items will be diverted to weapons production.

On 21 March 2024, Costa Rica's Ministerio de Comercio Exterior (COMEX) launched the Hoja de Ruta para el Fortalecimiento del Ecosistema de Semiconductores — the first national semiconductor roadmap published by any Latin American country — jointly presented with US Secretary of Commerce Gina Raimondo in the context of the CHIPS Act §103 ITSI Fund partnership. President Rodrigo Chaves Robles simultaneously signed an executive decree declaring the semiconductor industry and related industries of "interés público" (public interest) and directing COMEX to lead implementation. The roadmap is organised around four pillars: Talent (Human Talent Training Incentive programme, US$6M initial budget), Incentives (OECD BEPS Pillar Two-aligned fiscal/financial R&D incentives, Free Trade Zone regime strengthening under Law 7210), Investment Attraction (CINDE-led FDI promotion targeting ATP, advanced PCB, and design-house segments), and Regulatory Improvement (customs facilitation, IP reform, export-control alignment). Costa Rica is one of seven declared ITSI-fund partner economies and hosts Intel's largest non-US assembly and test site since 1997, alongside Applied Materials, ON Semiconductor, Coherent, MaxLinear, and Boston Scientific.

Malaysia's New Industrial Master Plan 2030 (NIMP 2030) is the fourth-edition national industrial master plan launched on 1 September 2023 by Prime Minister Anwar Ibrahim under the Ministry of Investment, Trade and Industry (MITI). Spanning seven years to 2030, NIMP 2030 adopts a mission-based approach with 4 missions, 21 strategies and 62 action plans, mobilising an RM95bn investment envelope (predominantly private-sector capital channelled through private equity and the capital markets). The plan targets a step-change in manufacturing-sector economic complexity, deeper local-industry linkages and expanded participation in global supply chains, with explicit numerical targets for the manufacturing sector's GDP contribution and annual growth by 2030.

On 20–21 December 2022 OFAC published two final rules (87 FR 78470 and 87 FR 78484) amending regulations across more than 30 sanctions programs to add general licenses (GLs) authorising four categories of humanitarian activity: (1) certain NGO transactions for disaster relief, health, democracy support, education, environmental protection, and peacebuilding; (2) provision of agricultural commodities, medicine, medical devices, replacement parts, and software updates for medical devices to blocked persons for personal, non-commercial use; (3) US government official-business transactions; and (4) official-business transactions of designated international organisations (e.g. UN, ICRC). The rules amended 29 CFR parts spanning Nicaragua, Iraq, Somalia, South Sudan, Yemen, and more than two dozen other sanctioned programs. The NGO GL excludes knowing fund transfers to blocked persons unless specified criteria are met, preserving the core blocking perimeter while lowering humanitarian-access friction.

Council Regulation (EU) 2022/2372, adopted 24 October 2022, establishes a binding framework empowering HERA (Health Emergency Preparedness and Response Authority) to activate emergency supply measures for crisis-relevant medical countermeasures — vaccines, therapeutics, PPE, medical devices, and in-vitro diagnostics — when a public health emergency at Union level is declared under Regulation (EU) 2022/2371. Emergency-mode powers include joint procurement on behalf of Member States, mandatory information requests to manufacturers on stockpiles and production capacity, accelerated R&D funding under the Emergency Research and Innovation Plan, and Union-level stockpile authority. This is the foundational binding instrument for the EU's post-COVID medical supply-chain resilience architecture; it is referenced by every subsequent EU pharma-resilience initiative including the Critical Medicines Act proposal (2025) and the 2025 MCM Strategy.

On 4 August 2022 OFAC formally published in the Federal Register nine general licenses (GLs 17–25) that had previously been made available only on OFAC's website under EO 14065 (Donetsk/Luhansk regions) and, for GL 25, also EO 13685 (Crimea). GL 17, which authorised wind-down of Donetsk/Luhansk transactions, had already expired on 23 March 2022. GLs 18–25 remain in force and authorise a structured set of humanitarian and civil-society carve-outs — covering agricultural commodities, medicine and medical devices, telecommunications, official international organisation business, personal remittances, internet-based communications, NGO activities, civil maritime services, and journalistic activities — within the otherwise restricted territory of Crimea, the so-called Donetsk People's Republic (DNR), and the Luhansk People's Republic (LNR).

On 22 March 2021, UAE Vice President and Prime Minister Sheikh Mohammed bin Rashid Al Maktoum launched Operation 300bn at Qasr Al Watan in Abu Dhabi — a 10-year national industrial strategy delivered by the newly created Ministry of Industry and Advanced Technology (MoIAT, established July 2020). The strategy targets raising the industrial sector's annual GDP contribution from AED 133bn (~USD 36bn) to AED 300bn (~USD 82bn) by 2031, lifting R&D spend from AED 21bn to AED 57bn (1.3% → 2% of GDP), and supporting more than 13,500 industrial SMEs through an AED 30bn (~USD 8.2bn) Emirates Development Bank (EDB) financing portfolio. Eleven priority sub-sectors are organised into three baskets: Stimulating Growth (food/beverage, pharmaceuticals, electrical equipment), Advanced Manufacturing (petrochemicals, rubber/plastics, machinery), and Industries of the Future (hydrogen, medical technology, space technology).